Our data also indicate that the IL-33/ST2 axis is not involved in the TSLP-mediated model of airway inflammation and that IL-33 is not a general therapeutic target to prevent the allergic asthma once AD develops. The gene discussed is TSLP; the disease is allergic asthma.